PharmNovo AB is a Swedish biopharmaceutical company based in Lund, established in 2008. It specializes in the development of therapeutic drugs aimed at treating neuro diseases, particularly hyper excitability disorders such as chronic pain. The company's leading product, PN6047, is designed to alleviate chronic pain and address issues of hypersensitivity. PharmNovo employs a research approach that integrates advanced chemistry and bioscience to create safe, effective, and non-addictive opioid alternatives for managing nervous system disorders. By focusing on neuroscience and translational medicine, PharmNovo aims to enhance the quality of life for individuals suffering from chronic pain.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.